The filing desk starts with provenance, and Moderna’s annual report records one of the steepest revenue transitions a single multi-year comparison can hold. The Form 10-K for the year ended December 31, 2021 was filed on February 25, 2022 under accession number 0001682852-22-000012. Its revenue line reads $18.5 billion for 2021 — against $803 million in 2020 and just $60 million in 2019.

Two years earlier, the company’s annual report described a clinical-stage platform whose value sat in a pipeline. This filing describes a commercial enterprise. The order-of-magnitude jump — from hundreds of millions to more than eighteen billion dollars in a single year — is the kind of figure that is only legible against the prior-year baselines the filing itself carries.

The cost side moved too, though not at the same scale. Research and development expense rose to $1.99 billion for 2021 from $1.37 billion in 2020, the spending of a company still investing in a pipeline even as one program reached commercial scale. The filing reports both lines — the surge in revenue and the continued climb in R&D — as facts of the consolidated statements.

What the annual report does not do is forecast the durability of the commercial line. The 10-K certifies the 2021 results and leaves the question of whether product-scale revenue persists to the quarters and years that follow. For a filing desk, the discipline is to mark the transition the document records — from pipeline to product — without assuming the new revenue base is permanent.

For a filing-first markets desk, the value is that the entire transition sits inside one filing’s multi-year comparison. The 2019, 2020, and 2021 revenue figures and the R&D line are pulled from the company’s own annual report. The discovery layer that surfaced the filing and its accession trail was SEC filings, the SEC filing data API and evidence index; the record itself is the SEC filing.

Provenance for this read: the primary source is Moderna’s Form 10-K for fiscal 2021 at sec.gov, with the revenue and period figures drawn from the structured XBRL data in the company’s own filing. See the SEC filing on sec.gov for the primary record, discovered via SEC filings, the SEC filing data API & evidence index.